Mustang Bio (MBIO) EBITDA (2016 - 2026)
Mustang Bio (MBIO) posted quarterly EBITDA of -$1.1 million for Q1 2026, down 318.18% year-over-year from $484916.7 in Q1 2025, and down 57.91% quarter-over-quarter from -$670000.0 in Q4 2025.
Mustang Bio (MBIO) EBITDA (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported EBITDA for 11 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 318.18% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$3.2 million (up 71.27% YoY), while the FY2025 annual figure was -$2.4 million, up 85.03% from the prior year.
- EBITDA slipped to -$1.1 million in Q1 2026 per MBIO's latest filing, from -$670000.0 in the prior quarter.
- Across five years, EBITDA topped out at -$253000.0 in Q1 2025 and bottomed at -$19.6 million in Q1 2022.
- Historically, EBITDA has averaged -$8.5 million across 5 years, with a median of -$8.5 million in 2024.
- Annual changes were most pronounced in 2025 — EBITDA soared 95.16% — and 2026, when it slumped 318.18%.
- Mustang Bio's EBITDA stood at -$19.4 million in 2022, then jumped by 55.02% to -$8.7 million in 2023, then jumped by 88.37% to -$1.0 million in 2024, then surged by 34.12% to -$670000.0 in 2025, then tumbled by 57.91% to -$1.1 million in 2026.
- Business Quant data shows MBIO's EBITDA at -$1.1 million in Q1 2026, -$670000.0 in Q4 2025, and -$624000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | -1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.17 Mn |
| Mar 31, 2026 | -1.06 Mn |
| Dec 31, 2025 | -670,000.00 |
| Sep 30, 2025 | -624,000.00 |
| Jun 30, 2025 | -885,000.00 |
| Mar 31, 2025 | -253,000.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | -8.54 Mn |
| Mar 31, 2024 | -5.23 Mn |
| Dec 31, 2023 | -8.74 Mn |
| Sep 30, 2023 | -10.31 Mn |
| Jun 30, 2023 | -13.89 Mn |
| Mar 31, 2023 | -16.32 Mn |
| Dec 31, 2022 | -19.43 Mn |
| Sep 30, 2022 | -18.85 Mn |
| Jun 30, 2022 | -18.24 Mn |
| Mar 31, 2022 | -19.64 Mn |
| Dec 31, 2021 | -20.12 Mn |
| Sep 30, 2021 | -17.08 Mn |